# Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

Study · id `cardio:ct-nct03191396` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03191396](<https://clinicaltrials.gov/study/NCT03191396>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03191396

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 577 participants.

## Technical summary

Registry record NCT03191396. Randomized; no masking; primary purpose treatment. Start 2017-06-27 (actual); primary completion 2018-07-09 (actual). Results posted on 2019-08-28.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 577 participants (enrolled count; ClinicalTrials.gov record NCT03191396, source copy `cardio:ctgov-nct03191396-2019-10-15`, retrieved 2026-10-26)
- Started: 2017-06-27 (actual) (ClinicalTrials.gov record NCT03191396, source copy `cardio:ctgov-nct03191396-2019-10-15`, retrieved 2026-10-26)
- Primary completion: 2018-07-09 (actual) (ClinicalTrials.gov record NCT03191396, source copy `cardio:ctgov-nct03191396-2019-10-15`, retrieved 2026-10-26)
- Completion: 2018-08-13 (actual) (ClinicalTrials.gov record NCT03191396, source copy `cardio:ctgov-nct03191396-2019-10-15`, retrieved 2026-10-26)
- Results first posted: 2019-08-28 (ClinicalTrials.gov record NCT03191396, source copy `cardio:ctgov-nct03191396-2019-10-15`, retrieved 2026-10-26)
- Countries: Bulgaria; Czechia; Finland; France; Germany; Hungary; Italy; Poland; Slovenia; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT03191396, source copy `cardio:ctgov-nct03191396-2019-10-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03191396-2019-10-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
- Acronym: SUSTAIN 10
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Semaglutide
- Intervention (Drug): Liraglutide
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10) (`cardio:pubmed-31539622`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 51aaac0215a16f76f961fcf69660a261941c1112e57924e59d4c4d9f1e63683e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
